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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic, systemic disease that 
primarily targets the synovium, leading to synovial inflammation and 
proliferation, loss of articular cartilage, and erosion of juxtarticular bone. 
The natural history of the disease is one of progressive joint damage and 
deformity and, in a sizeable minority, the development of extra-articular 
manifestations. Over the last few decades it has become increasingly 
apparent that chronic activation of the immune system, as observed in the 
pathogenesis of RA, is associated with changes in intermediary 
metabolism, potentially leading to increased risk of cardiovascular 
disease. There is evidence of association of multiple immune regulatory 
components (including tumour necrosis factor and interleukin-6) in RA.  
Dyslipidemia is a major risk factor for atherosclerosis and 
cardiovascular disease. In RA patients significant decrease levels of HDL 
cholesterol along with hypercholesterolemia is seen compared with 
controls. It is found that dyslipidemia can manifest in RA patients with 
both early and advanced disease. Thus altered lipoproteins along with an 
increase in lipid peroxidation products suggests that RA patients are at a 
high risk for the development of coronary heart disease. LDL is 
associated with the risk of coronary heart disease and also has been 
shown to undergo oxidation forming oxidized LDL, which leads to 
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phospholipid release, activating endothelial cells, thereby initiating an 
inflammatory process which leads to the formation of foam cells and 
subsequent fatty streaks. Under normal condition HDL exerts its anti 
atherogenic role by protecting LDL from oxidation. The present study 
showed that RA patients exhibited high TC and low HDL serum levels. 
The increment in TC was directly correlated with the increment of CRP 
level and ESR values. The decrement in HDL-C was inversely correlated 
with the increment of CRP level and ESR values. It suggested that 
inflammation is an important determinant for the reduced HDL-C levels 
observed in RA patients and the correlation between TC and ESR and 
CRP in active RA patients raises the possibility that cholesterol behave 
like an activity marker. C-reactive protein and ESR are acute phase 
reactants for RA which increase in active disease may contribute to 
atherosclerosis because it stimulates macrophage to produce tissue factor, 
a pro coagulant that is found in atherosclerotic plaque and significantly 
associated with risk of CVD in RA. The present study showed as well 
there is a significant correlation between HDL and duration of the 
disease, and inversely significant correlation between LDL and disease 
duration. These results are in agreement with other studies which found 
that effective treatment of an inflammatory process may prove beneficial 
for dyslipoproteinemia and possibly the risk of cardiovascular disease 
and related mortality. Active RA was associated with an adverse lipid 
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profile that improved significantly upon effective treatment of RA with 
disease-modifying anti-rheumatic drugs (DMARD) suggesting it was the 
decrease in RA disease activity that reversed the altered lipid profiles. 
The present study concluded that patients with RA were characterized by 
an atherogenic lipid profile, which improves after therapy. Thus, early 
intervention to control disease activity may reduce the risk of the 
atherosclerotic process and cardiovascular events in RA patients. 
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AIMS AND OBJECTIVES 
 
• To compare CRP level with HDL level in rheumatoid arthritis 
patients 
• To improve the long term survival of Rheumatoid arthritis 
patients by early detection of  dyslipidemia and timely 
institution of treatment 
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REVIEW OF LITERATURE 
RHEUMATOID ARTHRITIS 
Most common form of chronic inflammatory arthritis is 
Rheumatoid arthritis which is idiopathic in nature. It commonly 
presents with peripheral polyarthritis which is symmetric in nature. 
Rheumatoid arthritis can present with extra articular manifestations 
because of systemic nature of disease. Rheumatoid arthritis cause 
significant mortality and morbidity. Compared with general 
population, patients with Rheumatoid arthritis has short life 
expectancy. Mortality rate is two times higher than general 
population. Leading cause of death in patients with Rheumatoid 
arthritis is cardio vascular disease.  Because of chronic activation 
inflammation in Rheumatoid arthritis leads to changes in  the lipid 
profile.it accelerates atherosclerosis which leads to increased 
cardiovascular mortality and morbidity in rheumatoid arthritis 
patients.    
EPIDEMIOLOGY 
It affects 0.5 - 1% of adult population. In African and American 
countries it is around 0.2 - 0.4%. It has highest prevalence in Native 
Americans which is around 7%. 
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It affects adults between 25 to 55 years with increasing incidence. 
Incidence decreases after 75 years of age. Females are more commonly 
affected than males. Female to male ratio is 3:1. Highest female to male 
ratio is seen in Latin American and African. It is 6-8:1. 
Tumor necrosis factor production is enhanced by estrogen, which 
may be reason behind increased female prevalence. 
GENETIC CONSIDERATIONS 
First-degree relative of a patient have risk of 2-10 times greater 
than general population. Most important alleles are located within the 
major histocompatibility complex. One-third of genetic risk resides 
within this locus. Most of this risk is associated with allelic variation in 
the HLA-DRB1 gene. HLA-DRB1*0401 is associated with high risk of 
disease. Alleles associated with moderate risk are *0101, *0404, *0901 
and *1001. Most common alleles in Asians are *0405, and *0901. 
Several non-MHC- related genes also contribute like PTPN22/CTLA4. 
The peptidyl arginine deiminase type IV (PADI4) gene is another 
risk allele that encodes an enzyme involved in the conversion of arginine 
to citrulline and is postulated to play a role in the development of 
antibodies to citrullinated antigens. A polymorphism in PADI4 has been 
associated with RA only in Asian populations. 
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The most reproducible of these environmental links is cigarette 
smoking. Numerous cohort and case control studies have demonstrated 
that smoking confers a relative risk for developing RA of 1.5–3.5. In 
particular, women who smoke cigarettes have a nearly 2.5 times greater 
risk of RA, a risk that persists even 15 years after smoking cessation. A 
twin who smokes will have a significantly higher risk for RA than his or 
her monozygotic co-twin, theoretically with the same genetic risk, who 
does not smoke. Interestingly, the risk from smoking is almost 
exclusively related to RF and anti-CCP antibody-positive disease. People 
who are smoking, will be having more circulating level of antibody 
against CCP(cyclic citrullinated peptide). Normally airways are devoid of 
citrulline. When a person smokes, it will change the airway epithelium to 
have citrulline from arginine. Now our immune system will recognize 
this as foreign antigen, will produce antibody called as anti-CCP 
antibody.  
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This image represents normal joint & Rheumatoid joint In 
rheumatoid joint, there will be a long standing synovitis which leads to 
pannus formation. Pannus is nothing but hypertrophied synovium. It will 
start eroding the underlying cartilage & bone. Finally patients with 
synovitis will land up in erosive arthritis. That erosion will be classically 
seen in margin of joint (marginal erosion) there only bone is devoid of 
articular cartilage. Synovial fluid is filled with inflammatory cells and 
immune complex.     
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PATHOGENESIS OF RA 
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CLINICAL FEATURES ARE CLASSIFIED INTO  
1. ARTICULAR (most common) 
2. EXTRA ARTICULAR (30-40%)  
JOINT INVOLVEMENT: 
Joint pain/swelling/stiffness is common presenting symptom, 
which is more in early morning lasts around 1 hour and improves with 
physical activity. It affects small joints of hand and feet. It is symmetric 
in nature. Initially it can present as  
1. Mono articular 
2. Oligo articular  or 
3. Poly articular  
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EARLY INFLAMMATORY STAGE 
 
 
ADVANCED DEFORMITY STAGE 
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CONSTITUTIONAL SYMPTOMS 
These signs and symptoms include weight loss, fever, fatigue, 
malaise, depression, and in the most severe cases, cachexia; they 
generally reflect a high degree of inflammation and may even precede the 
onset of joint symptoms. In general, the presence of a fever of >38.3°C 
(101°F) at any time during the clinical course should raise suspicion of 
systemic vasculitis or infection.  
Commonly affected joints are 
1. Metacarpo phalangeal (MCP) joint 
2. Proximal interphalangeal (PIP) joint 
3. Wrist 
4. Metatarso phalangeal joint 
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Radiological evidence of temporo mandibular joint involvement is 
common. But it does not cause any functional significance. Usually axial 
skeleton involvement uncommon in RA. It is classical of 
spondyloarthropathy Thoracic and lumbar spines, sacroiliitis are usually 
not involved in RA. Rarely C1/C2 cervical segment can be affected. It 
will lead to atlanto-axial subluxation, that leads to cervical cord 
compressive myelopathy.  Damage to joint and soft tissues leads to 
chronic irreversible deformity. 
1. Swan neck deformity – Hyperextension of PIP  
                                       Flexion of DIP 
2. Boutonniere deformity – Flexion of PIP  
                                        Hyperextension of DIP 
3. Z line deformity – Subluxation of first MCP  
                              Hyperextension of first inter phalangeal joint  
4. Ulnar deviation - Subluxation of MCP  
                              Subluxation of PIP to volar side of hand 
5. Piano-key movement of Ulnar styloid – Subluxation of distal ulna 
6. Trigger finger - due to tenosynovitis of flexor tendon sheath 
7. Flat foot – Pes planovalgus due to involvement of mid tarsal joints. 
GEODES BONE CYST can be seen in RA affected joints.   
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SUBCUTANEOUS NODULES 
Subcutaneous nodules occur in 20–35% of patients with RA and 
are usually nontender, firm, and 1 cm or less in diameter. Subcutaneous 
nodules can be fixed or mobile and occur most frequently over pressure 
point areas such as the extensor aspect of the elbows, within the 
olecranon bursa, and over the Achilles tendon but also can overlie joints. 
Nodulosis over the sacrum, ischial tuberosities, occipital region of the 
scalp, or borders of the scapulae may develop in bedridden patients. 
Rarely, nodules develop within organ systems including the scleral layer 
of the eye, heart valves, lung, on the dural surface of the brain, or in the 
larynx. 
Rheumatoid nodules are strongly associated with rheumatoid factor 
(positive in >95% of cases). Recent epidemiologic studies demonstrate 
that patients with RA who smoke have a higher risk of developing 
nodules. Strongly seropositive individuals with nodulosis tend to carry a 
worse prognosis, with a higher propensity toward erosive and destructive 
rheumatoid disease. The mimics of subcutaneous rheumatoid nodules 
include tophi, xanthomas, Garrod knuckle pads (fibrous nodules on the 
dorsal surfaces of the PIP joints of patients with Dupuytren contractures), 
the nodules of multicentric reticulohistiocytosis and, in children, the 
nodules of acute rheumatic fever. On clinical grounds alone, even 
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experienced rheumatologists may be unable to distinguish RA with 
olecranon nodulosis from polyarticular gout with olecranon tophi. 
Excisional biopsy is sometimes necessary to establish the correct 
diagnosis. Rheumatoid nodules have characteristic—but not specific—
histologic findings of central fibrinoid necrosis with a rim of palisading 
fibroblasts. Histologically, rheumatoid nodules are indistinguishable from 
granuloma annulare (dermal or subcutaneous nodules not associated with 
arthritis) or from “benign nodules” which occur exclusively in children 
<18 years of age and are not associated with arthritis or with rheumatoid 
factor. 
Subcutaneous rheumatoid nodules may resolve with effective 
therapy of the associated articular disease. A subset of rheumatoid 
patients, however, experience paradoxical accelerated nodulosis with 
methotrexate therapy . Nodules in these patients are often found over the 
extensor aspect of the MCP and PIP joints of the fingers. Methotrexate 
should be discontinued when there is extensive proliferation of nodules, 
particularly with ulceration of overlying skin. 
Unfortunately, there is no effective therapy for this situation. Most 
alternative DMARDs have been tried in these cases but with only 
ccasional success. Symptomatic subcutaneous nodules located over 
pressure points can be surgically removed. The effectiveness of this 
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surgical approach, however, is limited by high rates of recurrence of 
nodules, poor wound healing, and secondary infection at the operative 
site, often with S aureus. Rheumatoid nodules in the lung may be solitary 
or multiple, and some are necrotic. Isolated reports suggest a possible link 
between leflunomide therapy and necrotic pulmonary nodules. 
Distinguishing rheumatoid pulmonary nodules from carcinoma can be a 
particularly difficult problem, even after extensive imaging evaluation 
with computed tomography (CT) and positron emission tomographic 
scans.  
CT-guided biopsy is usually the only certain means of 
differentiating between these possibilities. 
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RHEUMATOID NODULE 
 
SJOGREN’S SYNDROME 
Dryness of eyes and mouth is the most common ocular 
manifestation of RA. 
Approximately 30% of patients with RA have sicca symptoms due 
to secondary Sjögren syndrome. Mucosal dryness most commonly affects 
the mouth, the conjunctival surfaces of the eyes, and vagina. Dental 
caries, gingivitis, and accelerated tooth loss may occur due to the lack of 
adequate salivary lubrication. Patients frequently experience chronic 
“foreign body” sensations in their eyes, and women often develop 
recurrent monilial infections of the vaginal mucosa. 
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Care must be exercised in distinguishing typical Sjögren symptoms 
from xerostomia due to medications, particularly antidepressants. Chronic 
hepatitis C infection, which can cause polyarthritis, sicca symptoms, and 
rheumatoid factor, also can mimic RA with secondary Sjögren syndrome. 
Occasionally, it is difficult to distinguish RA with secondary Sjögren 
syndrome from primary Sjögren syndrome with polyarthritis. 
The diagnostic evaluations to establish xerophthalmia and 
xerostomia are those used for primary Sjögren syndrome. In contrast to 
primary Sjögren syndrome, antibodies to SS-A/Ro and to SS-B/La are not 
prevalent in the secondary Sjögren syndrome associated with RA. 
Compared to patients with primary Sjögren syndrome, 
hypergammaglobulinemia, interstitial nephritis, and distal renal tubular 
acidosis uncommonly develop in patients with RA and secondary Sjögren 
syndrome. Additional rare complications include the development of non-
Hodgkin large B cell lymphomas or mucosal associated lymphoid tumors 
(MALT). 
Treatment of secondary Sjögren syndrome is symptomatic. 
Artificial tears or cyclosporine 0.05% emulsion drops twice daily can 
ease ocular symptoms. Pilocarpine hydrochloride 5 mg orally three to 
four times daily or cevimeline 30 mg three times daily may be effective 
in promoting increased salivary production but can cause hyperhidrosis. 
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PULMONARY MANIFESTATION 
1. PLEURAL DISEASE –  
Most common pulmonary manifestation. It presents as 
pleuritic chest pain, pleural effusion.  
Pleural effusions are exudative in nature and 
characteristically pleural sugar will be very low(<30 mg%). 
2. PULMONARY NODULES –Solitary or multiple. 
3. RESPIRATORY BRONCHIOLITIS  
4. BRONCHIECTASIS 
5. CAPLAN’S SYNDROME – A variant of rheumatoid pulmonary 
nodulosis is Caplan syndrome . In 1953, Caplan described multiple 
rheumatoid nodules, some with cavitation, in the lungs of Welsh 
coal miners with RA. This pattern has also been reported in RA 
patients exposed to silica dust and asbestos, raising the question of 
whether Caplan syndrome is a combined “pneumoconiosis—RA” 
entity. 
6. ILD –  
Interstitial fibrosis of the lungs is one of the most dreaded 
complications of RA and often carries a guarded prognosis. The 
prevalence of clinically evident pulmonary fibrosis among RA 
patients is approximately 2–3%, and the prevalence of 
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asymptomatic pulmonary fibrosis detected by high-resolution CT 
(HRCT) is substantially higher. The cumulative incidence of 
clinical pulmonary fibrosis approaches 10%. 
Common in smokers & male 
Presents as dry cough and progressive dyspnea. 
Associated with anti CCP positivity 
Carries poor prognosis. 
7. CRICOARYTENOID ARTHRITIS can lead to hoarseness of voice  
CARDIAC MANIFESTATIONS 
It can involve pericardium, myocardium and endocardium. Though 
pericardium (pericarditis) is the most common site of involvement 
clinically manifests in less than 10 % of patients. RA patients are highly 
prone to have constrictive pericarditis .Commonest valvular abnormality 
is mitral regurgitation. Restrictive cardiomyopathy can result from 
deposition of amyloid by secondary amyloidosis. Cardiomyopathy can 
result from myocarditis or coronary artery disease. The most common 
cause of death in RA is CAD. Patients with high disease activity are 
highly prone to have adverse cardiac events. Low HDL is the most 
consistent finding in a background of high disease activity in RA.  
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VASCULITIS 
It occurs in patients with long standing disease. Affects less than 
1% of patients. Cutaneous signs are petechiae, purpura, digital infarcts, 
gangrene, livedo reticularis and vasculitic ulcer. Most common type of 
vasculitis is leukocytoclastic vasculitis. It will lead to classical small 
necrotic skin ulcer in hand it is called as Bywaters lesion. RA patients are 
uncommon to have RAYNAUD’S PHENOMENON. Rheumatoid 
Vasculitis rarely presents as multiple peripheral nerve palsy. 
 
 
BYWATERS LESION 
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PYODERMA GANGRENOSUM 
Pyoderma gangrenosum is an ulcerative neutrophilic dermatitis of 
unknown cause. It occurs in less than 1% of patients with RA and usually 
manifests a lower-extremity, deep ulcer with purplish, overhanging 
borders. Initial therapy most commonly involves glucocorticoids; there 
are some reports of success with anti-TNF agents and with cyclosporine. 
HEMATOLOGIC MANIFESTATIONS 
1. Normocytic normochromic anemia- severity of anemia correlate 
with degree of inflammation. 
2. Total and differential WBC count will be normal. If any patient 
having leukopenia in early stage of disease we have to think of 
drug induced rather than disease per se. 
3. Platelet- usually elevated because of acute phase reaction. Rarely 
immune-mediated thrombocytopenia will be present. 
4. Felty’s syndrome – rare. Presents as triad of neutropenia, 
splenomegaly and nodular RA. It occurs in late stages of disease. 
5. T cell large granular lymphocyte leukemia- due to indolent growth 
of LGL cells. It occurs in early stages of rheumatoid arthritis. 
6. Lymphoma- fourfold risk of lymphoma. Diffuse large B-cell 
lymphoma is most common histologic type. 
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NEUROLOGIC MANIFESTATIONS 
The most common neurologic complications of RA are 
compression neuropathies, particularly compression of the median nerve 
at the wrist (carpal tunnel syndrome) and compression of the ulnar nerve 
at the elbow or wrist. Rheumatoid vasculitis can cause mononeuritis 
multiplex and a mixed motor-sensory peripheral neuropathy. Atlantoaxial 
subluxation and basilar invagination can produce cervical myelopathy 
and brainstem compression. An unusual complication of RA is 
pachymeningitis-inflammation and thickening of dura mater-which 
presents as a clouded sensorium, cranial nerve abnormalities, and 
retardation of motor activity. Once an infectious etiology has been 
excluded, pachymeningitis is treated vigorously with glucocorticoids and 
appropriate DMARDs. 
OSTEOPOROSIS 
Inflammatory mediated activation of osteoclasts leads to 
generalized osteoporosis. Other factors contributing to osteoporosis are 
immobility and steroid abuse. FRAX algorithm is used to assess the 
fracture risk in future due to osteoporosis.  
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RENAL INVOLVEMENT 
Kidney involvement is interestingly absent in RA by disease per se. 
drugs are commonly linked to kidney involvement. Gold and 
penicillamine were used they are responsible for membranous 
nephropathy.no more they are used nowadays. Most important 
complication of rheumatoid arthritis is secondary amyloidosis, it can 
affect the kidney.  
EYE INVOLVEMENT 
Keratoconjunctivitis sicca due to secondary Sjögren syndrome is 
the most common ocular manifestation of RA. However, RA also can 
cause ocular inflammation, leading to episcleritis, scleritis, and peripheral 
ulcerative keratitis. Episcleritis , or inflammation of the episclera, 
manifests as a red eye due to hyperemia of this superficial ocular layer. 
Episcleritis produces irritation more than pain; it is not a vision-
threatening condition. Episcleritis may be self-limited but is often treated 
with topical corticosteroid drops. Of greater concern is inflammation of 
the sclera, the deeper, poorly vascularized layer of the eye. Scleritis is 
most commonly seen in patients who have had RA for 10 years or longer. 
Patients who are both rheumatoid factor and anti-CCP positive tend to 
have more intense ocular disease. Scleritis is a painful, persistent 
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condition. The eye typically is deep red. With time, thinning of the sclera 
can occur, imparting a bluish hue from the underlying choroid.  
Scleritis can be complicated by rheumatoid nodules forming and 
enlarging within the scleral layer. Unchecked, scleritis can produce 
scleromalacia perforans and can threaten the structural integrity of the 
globe. Inadequate or unsuccessful treatment can lead to irreversible 
blindness. Nodular scleritis is an urgent ophthalmologic problem that 
requires initiation of immunosuppressive therapy, most often with 
cyclophosphamide in combination with high-dose oral prednisone (eg, 1 
mg/kg/d). 
An additional serious ocular complication of RA is peripheral 
ulcerative keratitis with “melting” of the corneal epithelial layers. Again, 
this is seen in long-standing RA, often accompanied by rheumatoid 
vasculitis or other serious extra-articular manifestations. Peripheral 
ulcerative keratitis must be aggressively treated with immunosuppression 
using high-dose glucocorticoids and often cyclophosphamide. If the 
inflammation is successfully ameliorated, a corneal transplant can be 
performed to salvage vision. 
Scleritis, episcleritis are common. Scleromalacia perforans is the 
severe complication of RA. Uveitis is uncommon. 
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HYPOANDROGENISM  
Testosterone, Dehydroepiandrosterone and Luteinizing hormone 
levels are lower in postmenopausal women and men with Ra. Chronic 
inflammation leads to low testosterone level. Controlling of inflammation 
improves testosterone level. 
RHEUMATOID FACTOR 
             Seronegative patients have less extra-articular manifestations and 
better prognosis compared to seropositive patients. RF is nothing but 
antibody formed against Fc portion of IgG. Three isoforms of RF is 
occurring in serum of RA patients IgM, IgG and IgA. Commonly 
measured in laboratories is IgM isotype. Sensitivity of RF is 75 – 80 %. 
RA can’t be excluded by negative RF. RF positive patients are highly 
prone for severe erosive arthritis, extra articular manifestations. Patient 
who are positive for RF have poor prognosis 
           About 1-5 % of health population is positive for RF. RF is also 
positive in other connective tissue diseases and chronic infections like  
1. Sjogren’s syndrome 
2. SLE, 
3. Mixed essential cryoglobulinemia  
4. Subacute bacterial endocarditis,  
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5. Chronic hepatitis B and C. 
 
ANTI-CCP 
           It is more specific than RF. 
                             Sensitivity is 75-80%  
                             Specificity is 95%.  
It is helpful to differentiate RA from other inflammatory arthritis in 
early stages. Patients who are negative for one test (RF or Anti-CCP) may 
be positive for other test so it is complementary to go with both tests. 
Anti CCP positive patients are highly prone for severe erosive arthritis, 
extra articular manifestations most important is ILD. Patient who are 
positive for Anti-CCP have poor prognosis 
  
30 
 
SYNOVIAL FLUID ANALYSIS 
It  is  inflammatory  in  nature  with  WBC  count  between  5000 
to 50,000 per cubic micro liter. Predominant cell type is neutrophil. RF, 
anti-CCP antibodies and immune complexes is also found in synovial 
fluid.  
JOINT IMAGING 
Plain x-ray is commonly used but MRI is sensitive than Pain X-ray 
in early stages. Common X-ray findings are 
1. Juxta articular osteopenia,  
2. Soft tissue swelling , 
3. Symmetric joint space loss  
4. Subchondral bone erosions  
5.  Joint subluxation. 
Earliest Finding in X Ray is Marginal Erosion of Small Joints. 
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MARGINAL EROSION OF SMALL JOINTS 
 
 
CLASSICAL JOINT INVOLVEMENT IN RHEUMATOID 
ARTHRITIS  
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MRI- has greater sensitivity to early bone and bone marrow 
changes as well as synovitis and joint effusions. One of the early sign of 
inflammatory joint disease is bone marrow edema which can be easily 
picked up by MRI. Limiting factors are availability and cost.  
USG can be used to detect bony erosions in accessible joints. 
Synovitis is also reliably detected by USG. It has advantages of lack of 
radiation, portability and low cost. 
DIAGNOSIS 
             ACR-EULAR 2010 classification criteria now is used for 
diagnose RA. Main of aim revising older 1987 ACR classification criteria 
is to diagnose RA patients at early stages and introduction of disease 
modifying therapy at early stages. Serum anti-cyclic citrullinated 
antibodies is included in newer criteria which is more specific for RA 
than RF. Rheumatoid nodules and radiographic joint damage is not 
included in newer criteria because both of changes occurring in late 
stages of RA. This criteria is applicable to newly presenting patients. 
They must have at least one joint involvement with definite clinical 
synovitis.  
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CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS 
  SCORE 
JOINT 
INVOLVEMENT  
1 large joint 
2-10 large joints  
1-3 small joints 
4-10 small joints 
>10 joints ( at least 1 small joint) 
0 
1 
2 
3 
5 
SEROLOGY Negative RF and negative ACPA 
Low positive RF or anti-CCP (≤3 
times) 
High positive RF or anti-CCP 
(>3times) 
0 
2 
3 
ACUTE-PHASE 
RECTANTS 
Normal CRP and ESR 
Abnormal CRP and ESR 
0 
1 
DURATION OF 
SYMPTOMS 
<6 Weeks 
≥6 Weeks 
0 
1 
Score 6/10 is diagnosis of Rheumatoid arthritis. 
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DAS28 (Disease Activity Scoring – 28) 
DAS28 to assess improvement and progression of RA. It is a 
composite measure. It includes four parameters 
1. Number of joints showing tenderness  
2. Number of joints showing swelling 
3. ESR or CRP 
4. Subjective assessment of disease activity     
Joints to be assessed 
1. MCP 
2. PIP 
3. Wrist 
4. Elbow 
5. Shoulder 
6. Knee 
Ankle and MTP is not included.   
Values range from 2.0 to 10.0 
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SCORE DISEASE ACTIVITY 
>5.1 High disease activity 
5.1 to 3.2 Moderate disease activity 
3.2 to 2.6 Low disease activity 
<2.6 Remission 
 
TREATMENT OF RHEUMATOID ARTHRITIS 
Drugs used in the treatment of RA are together called as DMARDs  
DMARDs are so named because of their ability to slow or prevent 
structural progression of RA. 
1. Non-biological agents 
NSAIDs, 
Glucocorticoids 
Glucocorticoids in low doses (eg, prednisone 5–10 mg daily) can 
provide rapid, symptomatic improvement of articular disease and 
significantly slow the radiographic progression of RA. Glucocorticoids 
should be used rarely, if ever, as monotherapy for RA but can help 
control synovial inflammation while initiating therapy with the slow-
acting synthetic DMARDs or when the response to DMARDs is 
suboptimal. 
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The toxicities of long-term glucocorticoid therapy are considerable 
and are dose-dependent. Therefore, prednisone, the most commonly used 
glucocorticoid, generally should not be used in doses higher than 10 mg 
daily to treat articular disease and, after initiation of DMARD therapy, 
should be slowly tapered off or to the lowest effective dose. Long-term 
therapy with prednisone in doses of ≥7.5 mg/d orally is associated with 
an increased risk of both vertebral and hip fractures. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) play only a minor 
role, if any, in slowing progression of RA and, therefore , should not be 
used as the sole therapy for RA. The role of NSAIDs in RA is limited to 
symptomatic relief. The gastrointestinal toxicity of NSAIDs is a major 
issue for RA patients, who often have multiple risk factors for 
gastrointestinal toxicity. The use of protein pump inhibitors reduces the 
incidence of clinically significant gastrointestinal side effects. Intra-
articular injections of glucocorticoids can suppress joint inflammation for 
several months and can be a useful addition to DMARD therapy, 
especially when there is residual activity in large joints (eg, wrists, 
knees). In many cases, patients benefit from consultation with physical 
and occupational therapists regarding range of motion exercises, joint 
protection, and assistive devices. 
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CONVENTIONAL DMARDS  
a. Methotrexate (DRUG OF CHOICE) 
Methotrexate is the preferred synthetic DMARD of most 
rheumatologists. Many patients with RA have a durable, clinically 
meaningful response to methotrexate, which also slows radiographic 
progression of the disease. While effective as monotherapy, methotrexate 
also is the anchor drug in most successful combinations of synthetic 
DMARDs, and biologic agents are more effective when used 
concomitantly with methotrexate. 
Methotrexate is administered as a single dose once a week , never 
on a daily basis (toxicity is substantially greater when the same amount of 
drug is administered on a daily basis rather than as a weekly pulse). The 
typical starting dose is 7.5 mg orally once a week; the dose then is 
increased by 2.5 mg to 7.5 mg increments as needed to a maximum of 
20–25 mg. Oral absorption of methotrexate is variable; therefore, 
subcutaneous methotrexate may be effective if the response to oral 
methotrexate is suboptimal. Oral folate (1–4 mg daily) reduces side 
effects and should be administered concomitantly. Monitoring of blood 
cell counts, liver transaminase levels, and serum creatinine should be 
done every 12 weeks (every 2–4 weeks during initiation or after dose 
adjustments) for the duration of methotrexate therapy. 
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Contraindications to methotrexate 
a. Preexisting liver disease 
b. infection with hepatitis B or C 
c. ongoing alcohol use 
d. renal impairment  
Oral ulcers, nausea, hepatotoxicity, bone marrow suppression, and 
pneumonitis are the most commonly encountered toxicities. With the 
exception of pneumonitis (which is a hypersensitivity reaction), these 
toxicities respond to dose adjustments and are reduced by the 
concomitant use of folic acid. Renal function is critical for clearance of 
methotrexate and its active metabolites; previously stable patients may 
experience severe toxicities when renal function deteriorates. 
Pneumonitis, while rare, is unpredictable and may be fatal, particularly if 
the methotrexate is not stopped or is restarted. 
b. Hydroxychloroquine  
Hydroxychloroquine is frequently used for the treatment of RA, 
usually in combination with other synthetic DMARDs, particularly 
methotrexate. It has the least toxicity of any of the DMARDs but also is 
the least effective as monotherapy. Hydroxychloroquine is given orally at 
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a dose of 200–400 mg daily. An uncommon but serious complication is 
retinal toxicity, which correlates with cumulative dose and can be 
prevented by regular screening. The risk of retinal toxicity increases 
substantially after 5–7 years of use or a cumulative dose of 1000 g. At a 
minimum, patients should have a baseline ophthalmologic examination 
within 1 year of initiation of hydroxychloroquine and annual screening 
examinations after 5 years of therapy. Earlier, more frequent screenings 
are indicated for patients with risk factors (daily dose >400 mg or >6.5 
mg/kg ideal body weight for patients of short stature, kidney or liver 
dysfunction, other retinal disease, age >60 years). 
c. Sulfasalsazine  
Sulfasalazine is an effective treatment when given in doses of 1–3 
g daily, often in combination with methotrexate, hydroxychloroquine, or 
both. Recommendations for laboratory monitoring are the same as for 
methotrexate. 
d. Leflunomide   
Leflunomide, a pyrimidine antagonist, appears comparable in 
effectiveness to methotrexate. It is given daily in an oral dose of 10–20 
mg and has a very long half-life. The most common toxicity is diarrhea, 
which may respond to dose reduction. Like methotrexate, leflunomide 
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has hepatotoxicity, and recommendations for laboratory monitoring are 
the same as for methotrexate. Because leflunomide is teratogenic and has 
an exceptionally long half-life, women who have previously received 
leflunomide (even if therapy was years ago) should have blood levels 
drawn if they wish to become pregnant.  Oral cholestyramine can rapidly 
eliminate leflunomide if toxicity occurs or if pregnancy is being 
considered. 
2. Biological DMARDs 
TNF BLOCKERS  
ETANERCEPT 
INFIXIMAB  
ADALIMUMAB 
CERTOLIZUMAB 
GOLIMUMAB  
Anti-TNF agents should be avoided in patients with active 
infection or a history of hypersensitivity to these agents and are 
contraindicated in patients with chronic hepatitis B infection or class 
III/IV congestive heart failure. The major concern is the increased risk for 
infection, including serious bacterial infections, opportunistic fungal 
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infection, and reactivation of latent tuberculosis. For this reason, all 
patients are screened for latent tuberculosis according to national 
guidelines prior to starting anti-TNF therapy. In the United States, 
patients are skin tested using an intradermal injection of purified protein 
derivative (PPD); individuals with skin reactions of more than 5 mm are 
presumed to have had previous exposure to tuberculosis and are evaluated 
for active disease and treated accordingly. The QuantiFERON IFN-γ 
release assay may also be used in selected circumstances to screen for 
previous exposure to tuberculosis.  
IL 1 ANTAGONIST 
ANAKINRA 
CD 20 ANTAGONIST 
RITUXIMAB 
- It carries risk of progressive multifocal leukoencephalopathy.   
SIGNAL 2 INHIBITOR (CO-STIMULATION INHIBITOR) 
ABATACEPT 
IL 6 RECEPTOR ANTAGONIST  
- TOCILIZUMAB 
- Newly approved drug by  FDA  
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- Humanized monoclonal antibody directed against soluble and 
membrane forms of IL-6 receptor. 
- Dyslipidemia is one of the adverse effect the drug  
JANUS KINASE PATHWAY INHIBITOR 
TOFACITINIB: 
- Newly approved drug by  FDA  
- Oral JAK inhibitor  
- Small-molecule inhibitor that primarily inhibits JAK1 & JAK3 
pathway. 
- Dyslipidemia is one of the adverse effect the drug 
- Tofacitinib can be used as monotherapy or in combination with 
methotrexate.  
As mentioned earlier, methotrexate is the DMARD of first choice 
for initial treatment of moderate to severe RA. Failure to achieve 
adequate improvement with methotrexate therapy calls for a change in 
DMARD therapy, usually transition to an effective combination regimen. 
Effective combinations include: methotrexate, sulfasalazine, and 
hydroxychloroquine (oral triple therapy); methotrexate and leflunomide; 
and methotrexate plus a biological. The combination of methotrexate and 
an anti-TNF agent, for example, has been shown in randomized, 
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controlled trials to be superior to methotrexate alone not only for 
reducing signs and symptoms of disease, but also for retarding the 
progression of structural joint damage. Predicting which patients will 
ultimately show radiologic joint damage is imprecise at best, although 
some factors such as an elevated serum level of acute-phase reactants, 
high burden of joint inflammation, and the presence of erosive 
disease are associated with increased likelihood of developing structural 
injury. 
In 2012 a joint task force of the ACR and EULAR updated the 
treatment guidelines for RA. They do make a distinction between patients 
with early RA (<6 months of disease duration) and patients with 
established RA. These guidelines highlight the need to switch or add 
DMARD therapy after 3 months of worsening or persistent 
moderate/high disease activity. If disease still persists after 3 months of 
intense DMARD therapy, addition of a biologic agent is warranted. 
Treatment with a biologic agent or aggressive combination DMARD 
therapy was also recommended as initial therapy in certain patients with 
high disease activity and poor prognosis. However, it has not been clearly 
established that this more intensive initial approach is superior to starting 
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with methotrexate alone and, in the absence of an inadequate therapeutic 
response, moving rapidly to combination therapy. Some patients may not 
respond to an anti-TNF drug or may be intolerant of its side effects. 
Initial responders to an anti-TNF agent that later worsen may benefit 
from switching to another anti- TNF agent.  
The 2012 guidelines recommend that with loss or lack of 
effectiveness of anti-TNF after 3 months, one should switch to another 
anti-TNF or non-TNF biologic agent. In patients with high disease 
activity and a serious adverse event from an anti-TNF agent, a non-TNF 
drug should be used. Studies have also shown that oral triple therapy 
(hydroxychloroquine, methotrexate, and sulfasalazine) is a reasonable 
first step for the treatment of early RA, including its use as a step-up 
strategy where treatment is initiated with methotrexate alone and then 
combined at 6 months with hydroxychloroquine and sulfasalazine if the 
disease is not adequately controlled. 
3. PHYSICAL THERAPY AND ASSISTIVE DEVICES 
All patients should receive a prescription for exercise and physical 
activity. Dynamic strength training, community-based comprehensive 
physical therapy, and physical-activity coaching (emphasizing 30 min of 
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moderately intensive activity most days a week) have all been shown to 
improve muscle strength and perceived health status. Foot orthotics for 
painful valgus deformity decrease foot pain and resulting disability and 
functional limitations. Judicious use of wrist splints can also decrease 
pain; however, their benefits may be offset by decreased dexterity and a 
variable effect on grip strength. 
4. SURGERY 
Surgical procedures may improve pain and disability in RA—most 
notably the hands, wrists, and feet, typically after the failure of medical 
therapy with varying degrees of reported long-term success. For large 
joints, such as the knee, hip, shoulder, or elbow, total joint arthroplasty is 
an option for advanced joint disease. A few surgical Soptions exist for 
dealing with the smaller hand joints. Silicone implants are the most 
common prosthetic for MCP arthroplasty and are generally implanted in 
patients with severe decreased arc of motion, marked flexion 
contractures, MCP joint pain with radiographic abnormalities, and severe 
ulnar drift. Arthrodesis and total wrist arthroplasty are reserved for 
patients with severe disease who have substantial pain and functional 
impairment. These two procedures appear to have equal efficacy in terms 
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of pain control and patient satisfaction. Numerous surgical options exist 
for correction of hallux valgus in the forefoot, including arthrodesis and 
arthroplasty, as well as primarily arthrodesis for refractory hind foot pain. 
PREGNANCY & RA 
Pregnancy Up to 75% of female RA patients will note overall 
improvement in symptoms during pregnancy, but often will flare after 
delivery. Flares during pregnancy are generally treated with low doses of 
prednisone; hydroxychloroquine and sulfasalazine are probably the safest 
DMARDs to use during pregnancy. Methotrexate and leflunomide 
therapy are contraindicated during pregnancy due to their teratogenicity 
in animals and humans. The experience with biologic agents has been 
insufficient to make specific recommendations for their use during 
pregnancy. Most rheumatologists avoid their use in this setting; however, 
exceptions are considered depending on the circumstances. 
ELDERLY PATIENTS WITH RA 
Elderly Patients RA presents in up to one-third of patients after the 
age of 60; however, older individuals may receive less aggressive 
treatment due to concerns about increased risks of drug toxicity. Studies 
suggest that conventional DMARDs and biologic agents are equally 
  
47 
 
effective and safe in younger and older patients. Due to comorbidities, 
many elderly patients have an increased risk of infection. Aging also 
leads to a gradual decline in renal function that may raise the risk 
for side effects from NSAIDs and some DMARDS, such as methotrexate. 
Renal function must be taken into consideration before prescribing 
methotrexate, which is mostly cleared by the kidneys. To reduce the risks 
of side effects, methotrexate doses may need to be adjusted downward for 
the drop in renal function that usually comes with the seventh and eighth 
decades of life. Methotrexate is usually not prescribed for patients with a 
serum creatinine greater than 2 mg/dL. 
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MATERIALS AND METHODS 
STUDY POPULATION 
This study is to be conducted in 100 patients (Control 50 & 50 
cases of rheumatoid arthritis patients) attending Rheumatology & general 
medicine Outpatient department at Govt Rajaji hospital, Madurai. 
Inclusion criteria 
1. All (Male/Female) Rheumatoid arthritis patients (Irrespective of 
disease duration and treatment duration) according to ACR-
EULAR criteria. 
2. Age 30-50 Years 
Exclusion criteria 
1. Patients with Rheumatoid arthritis on biological agents 
(TOFACITINIB/TOCILIZUMAB)    
2. Known Diabetic/CAD/CKD/Hereditary Dyslipidemia 
3. Metabolic syndrome  
2. Obesity 
3. Hypothyroidism   
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ANTICIPATED OUTCOME 
Increased prevalence of dyslipidemia (low HDL) in Rheumatoid 
arthritis patients with high CRP level.  
DATA COLLECTION 
          The following information collected from patients who attended 
the Rheumatology/general medicine clinic in the form of Age, Sex, 
Duration of symptoms, Anthropometry measurements, Biochemical 
parameters [Rheumatoid factor, lipid profile ESR, CRP], Complication of 
Rheumatoid arthritis. 
I excluded the patient with Patients with Rheumatoid arthritis 
patient on biological agents (TOFACITINIB/TOCILIZUMAB), those   
on drugs impairing lipid metabolism, conditions associated with 
impairing lipid metabolism.  
LABORATORY INVESTIGATIONS 
 FASTING PLASMA GLUCOSE 
 TWO-HOURS PLASMA GLUCOSE  
 FASTING LIPID PROFILE 
 ERYTHROCYTE SEDIMENTATION RATE  
 C- REACTIVE PROTEIN 
 RHEUMATOID FACTOR 
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DESIGN OF STUDY 
         Observational study. 
PERIOD OF STUDY 
6 MONTHS (MARCH 2016 TO AUGUST 2016) 
COLLABORATING DEPARTMENTS: 
Department of Pathology 
Department of Biochemistry 
Department of Microbiology 
ETHICAL CLEARANCE: obtained  
CONSENT: Individual written and informed consent. 
STATISTICAL ANALYSIS: For continuous variables, Independent 
sample t-test was performed to find the differences between cases and 
controls and for categorical variables Pearson’s chi-square test was 
performed. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  NIL 
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PARTICIPANTS 
This study is to be conducted in 100 patients (Control 50 & 50 
cases of rheumatoid arthritis) attending Rheumatology & General 
medicine Outpatient department at Govt Rajaji hospital, Madurai. 
STATISTICAL METHODS 
All data were entered in Excel 2007 and statistical analysis was 
performed using the statistical software SPSS 16.0.  Data were expressed 
as frequency (with percentages), mean values (with SD) and minimum 
and maximum values. For continuous variables, Independent sample t-
test was performed to find the differences between cases and controls and 
for categorical variables Pearson’s chi-square test was performed.  
Correlation was performed to find the relationship between two 
continuous variables.  Results were defined as statistically significant 
when the P value (2-sided) was less than 0.05. 
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RESULTS 
Gender 
Group 
Cases Controls 
No % No % 
Male 7 14.0 7 14.0 
Female 43 86.0 43 86.0 
Total 50 100.0 50 100.0 
 
 
In our study, total cases are 100 (50 cases and 50 controls). Among 
that 86% are female, 14% are male in both case group and control group.  
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Age Group 
(in yrs) 
Group 
Cases Controls 
No % No % 
30 – 34 16 32.0 16 32.0 
35 – 39 21 42.0 18 36.0 
40 – 44 8 16.0 11 22.0 
45 – 49 5 10.0 5 10.0 
Total 50 100.0 50 100.0 
 
 
 In case group, cases are in the age of  30-34 yrs (32%), 35-39yrs 
(42%) 40-44yrs (16%) 45-49yrs (10%), majority in the age of 30-39yrs.  
In control group cases  are in the age of  30-34 yrs (32%), 35-39yrs 
(36%) 40-44yrs (22%) 45-49yrs (10%). 
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 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
Age (in yrs) 37.4±4.5 (30, 48) 37.5±4.5 (30, 47) 
 
In rheumatoid arthritis case group, mean age of onset is 37.4yrs. 
 
RF 
Group 
Cases Controls 
No % No % 
Positive 42 84.0 - - 
Negative 8 16.0 50 100.0 
Total 50 100.0 50 100.0 
p-value P<0.001 (Significant) 
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Rheumatoid factor positivity seen only in case group, not in control 
group. Positive cases are about 84% in case group. Comparing with case 
and control group rheumatoid factor positivity is significant (p <0.001). 
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 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
ESR 46.3±22.8 (13, 120) 13.7±2.7 (9, 20) 
p-value <0.001 
 
 
ESR values in case group minimum value  13mm/Hr, maximum 
value  120mm/Hr, mean value is 46.3mm/Hr. In control group ESR is 
within normal range. Comparing ESR level in case and control group, 
ESR level is statistically significant in case group (p value <0.001) 
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 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
CRP 7.9±5.5 (0.3, 22.4) 0.6±0.2 (0.1, 1.2) 
p-value <0.001 
 
 
CRP level in case group minimum level is 0.3mg/dl, maximum 
level is 22.4mg/dl, mean value is 7.9mg/dl. In control group CRP is 
within normal range. Comparing CRP level in case and control group, 
CRP level is statistically significant in case group (p value <0.001) 
  
58 
 
 
 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
HDL 41.0±7.4 (29, 59) 54.3±4.2 (46, 63) 
p-value <0.001 
 
 
HDL is in the normal range in control group. In case group HDL is 
significantly low . Comparing case and control group HDL level is 
statistically significant p value (<0.001) in case group. 
 
 
  
59 
 
 
 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
Total 
Cholesterol 
180.6±20.6 (156, 256) 173.7±9.5 (156, 190) 
p-value 0.033 
 
  
Total cholesterol is in the normal range in control group. 
Comparing case and control group Total cholesterol level is statistically 
significant p value (0.033). 
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 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
LDL 109.7±15.9 (88, 156) 105.3±8.2 (88, 123) 
p-value 0.082 
 
 
 
LDL is in the normal range in control group. Comparing case and 
control group LDL level is not statistically significant p value (<0.082). 
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 Group 
Cases Controls 
N=50 N=50 
Mean±SD (min, max) Mean±SD (min, max) 
Triglyceride 140.4±18.1 (110, 190) 124.2±11.8 (100, 145) 
p-value P<0.001 
 
 
TG is in the normal range in control group. Comparing case and 
control group TG level is statistically significant p value (<0.001). 
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Correlation between Lipid profile and ESR (mm/Hour) for 
Rheumatoid Arthritis patients 
Lipid profile 
Correlation co-
efficient (r) 
p-value 
TC mg/dl 0.782 <0.001 
LDL mg/dl 0.642 <0.001 
HDL mg/dl -0.798 <0.001 
TG mg/dl 0.831 <0.001 
 
In case group TC,LDL,TG levels are directly proportional to ESR 
level (p value <0.001 ). HDL level is inversely proportional to ESR level 
(p value <0.001 ). Correlation co efficient for HDL is -0.798 . In control 
group ESR, lipid profile are in normal range. No correlation is found in 
control group regarding ESR and TC,HDL,LDL,TG levels. ESR and 
HDL level correlation in RA case group, it is statistically significant (p 
value <0.001). 
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Correlation between Lipid fractions and CRP (mg/dl) for 
Rheumatoid Arthritis patients 
Lipid fractions 
Correlation co-efficient 
(r) 
p-value 
TC mg/dl 0.738 <0.001 
LDL mg/dl 0.615 <0.001 
HDL mg/dl -0.791 <0.001 
TG mg/dl 0.816 <0.001 
 
In case TC,LDL,TG levels are directly proportional to CRP level (p 
value <0.001 ). HDL level is inversely proportional to CRP level (p value 
<0.001 ). Correlation co efficient for HDL is -0.791. In control group 
CRP, lipid profile is in normal range. No correlation is found in control 
group regarding CRP and TC, HDL,LDL,TG levels. CRP and HDL level 
correlation in RA case group, it is statistically significant (p value 
<0.001).   
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Fig (1): Correlation between high density lipoprotein-cholesterol  
and Erythrocyte Sedimentation Rate 
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Fig (2): Correlation between Total Cholesterol 
and Erythrocyte Sedimentation Rate 
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Fig (3): Correlation between low density lipoprotein-cholesterol 
and Erythrocyte Sedimentation Rate 
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Fig (4): Correlation between Triglyceride and 
Erythrocyte Sedimentation 
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Fig (5): Correlation between high density lipoprotein-cholesterol 
and C-reactive protein 
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Fig (6): Correlation between Total Cholesterol  
and C-reactive protein 
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Fig (7): Correlation between low density lipoprotein-cholesterol  
and C-reactive protein 
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Fig (8): Correlation between Triglyceride and  
C-reactive protein 
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DISCUSSION 
Rheumatoid arthritis (RA) is a proatherogenic disease associated 
with increased cardiovascular (CV) mortality.1 2 Besides genetic and 
traditional CV risk factors,3 4 chronic inflammation has emerged as a 
pivotal component implicated in the development of this process. A 
chronic  inflammatory burden, determined by the  mean values of C-
reactive protein (CRP)  was associated with subclinical atherosclerosis 
and increased risk of CV events.5 6 In a large retrospective cohort study, 
CV disease-related mortality was increased in RA patients with elevated 
measures of inflammation markers.7 The presence of a proinflammatory 
state leads to a decrease of HDL cholesterol in patients with RA.8  The 
anti-inflammatory effect, DMARD agents have demonstrated a reduction 
of the CV death rate in patients with RA.9–12 This reduction in the rate 
of CV events seems to be directly related to better control of the 
rheumatic disease. Therefore, the relationship between CV disease and 
lipid levels in patients with RA may be different from that observed in the 
general population. Chronic inflammation leads to oxidative changes that 
alter HDL structure and reduce apolipoprotein-A-I in patients with active 
RA.13 Levels of paraoxonase-1, an antioxidant enzyme associated with 
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HDL, are lower in patients with RA compared with healthy controls.14 
Therefore, because of inflammation there is an impairment of the normal 
antiinflammatory,  antioxidate and cardioprotective function of HDL 
cholesterol that turns out to be proinflammatory.  A recent study that 
assessed a retrospective cohort using 2005–2010 data supported the 
association of inflammatory markers and serum lipids with the risk of CV 
events in RA.15 This study implied that inflammatory markers and HDL 
cholesterol levels are associated with increased and reduced incident CV 
disease, respectively.  According to their results, higher CRP and 
erythrocyte sedimentation rate levels and lower HDL cholesterol levels 
were associated with higher incidence of myocardial infarction.15 
HDL level is inversely proportional to ESR level (p value <0.001) 
in CASE GROUP. Correlation co efficient for HDL is -0.798 (p value 
<0.001). HDL level is inversely proportional to CRP level (p value 
<0.001). Correlation co efficient for HDL is -0.791 (p value <0.001) in 
CASE GROUP.  
In control group CRP,ESR,lipid profile is in normal range.     
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No correlation is found in control group regarding CRP/ESR and 
TC, HDL,LDL,TG levels.  
Semb et al16 showed that intensive treatment with statins led to a 
comparable decrease in lipid levels and a 20% reduction in overall 
risk of CV disease in patients with and without inflammatory joint 
disease. A significant reduction of CRP levels in patients with RA 
taking statins compared with placebo has also been observed.16  In a 
randomised controlled trial of atorvastatin in RA, McCarey et al17 
demonstrated a moderate decrease in disease activity and a significant 
reduction in total cholesterol and LDL cholesterol in statin-treated 
patients with RA.   
Early diagnosis and early introduction of treatment will reduce 
disease activity and control inflammation that will reduce risk of 
cardiovascular disease and improve long term survival of Rheumatoid 
arthritis patients. 
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LIMITATION 
 
- Sample size is small. 
- The study population involved patients seeking medical care in 
our hospital which is a tertiary care center and hence they may 
not represent the general population. 
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SUMMARY 
This observational study was conducted to identify impaired lipid 
metabolism in Rheumatoid arthritis patients and to compare CRP level 
with HDL level in rheumatoid arthritis patients and to improve the long 
term survival of Rheumatoid arthritis patients by early detection of  
dyslipidemia and timely institution of treatment 
          With 50 RA patients & 50 CONTROL cases were selected 
carefully and were evaluated on clinical and laboratory aspects after 
institutional ethical clearance with an informed consent. The data were 
entered in Microsoft Excel spread sheet and analysed statistically. 
  Irrespective of duration of disease and treatment, disease activity is 
found to be important key factor in induction of impaired lipid 
metabolism and other cardiovascular risk factors. 
 So with early diagnosis and early introduction of treatment we can 
reduce the prevalence of dyslipidemia in Rheumatoid arthritis patient. 
With all these measures we can reduce the risk of cardiovascular disease 
and improve long term survival of Rheumatoid arthritis patients. 
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CONCLUSION 
 Long duration of disease and disease activity is important risk 
of factor dyslipidemia. 
 Impaired LIPID metabolism carries high risk of cardiovascular 
disease. 
 Patients with active RA were characterized by an atherogenic 
lipid profile. 
 The decrement in HDL-C level was inversely correlated with 
the increment of CRP level in most of clinical studies.  
 Thus, early intervention to control disease activity may reduce 
the risk of the atherosclerotic process and cardiovascular events 
in RA patients. 
 Active RA was associated with an adverse lipid profile that 
improved significantly upon effective treatment of RA with 
disease-modifying anti-rheumatic drugs (DMARD) suggesting 
it was the decrease in RA disease activity that reversed the 
altered lipid profiles. 
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 Early diagnosis and early introduction of treatment will reduce 
disease activity and control inflammation that will reduce risk 
of cardiovascular disease and improve long term survival of 
Rheumatoid arthritis patients. 
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ANNEXURE 
PROFORMA 
Name: 
Age / Sex: 
Occupation: 
Presenting complaints: 
 H/o joint pain/swelling/deformity 
 H/o early morning stiffness,  
 H/o fever,  
 H/o malaise, 
 H/o breathing difficulty,  
 H/o chest pain,   
 H/o foreign body sensation in eyes, 
 H/o Redness of eye  
 H/o cough with expectoration 
 H/o Hemoptysis 
 H/o nodule over bone 
  
 H/o weakness of limbs/sensory disturbance 
 H/o abdominal pain/ distension 
 H/o leg swelling  
 H/o Leg ulcer 
 H/o Dry eye/mouth 
 H/o swelling of parotid region   
Past History: 
 H/o DM 
 H/o HT 
 H/o TUBERCULOSIS 
 H/o CAD  
 H/o COPD 
 H/o STROKE/ PERIPHERAL VASCULAR DISEASE 
 H/o CKD 
 H/o ENDOCRINOPATHIES  
 H/o DYSLIPIDEMIC SYNDROME 
 H/o DRUG INTAKE 
  
Clinical Examination: 
General Examination: 
Consciousness, 
Pallor,  
Jaundice,  
Clubbing, 
Lymphadenopathy,  
Pedal edema, 
Rheumatoid Nodule, 
Skin ulcer 
BMI: 
Vitals: 
PR 
RR 
BP  
SPO2 
 
  
System examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
Musculoskeletal examination: 
Laboratory investigations: 
 FBS,PPBS,RFT 
 THYROID FUNCTION TEST 
 FASTING LIPID PROFILE 
 RHEUMATOID FACTOR 
 ERTHROCYTE SEDIMENTATION RATE 
 C-REACTIVE PROTEIN 
 
 
 
  
KEY WORDS (ABBREVIATIONS) 
RA   -  Rheumatoid arthritis 
RF   -  Rheumatoid factor 
TNF   -  Tumor necrosis factor 
IL   -  Interleukin 
ACR-EULAR -  American college of Rheumatology-  
European league against Rheumatism 
DMARDs  -  Disease modifying antirheumatic drugs  
CCP   - cyclic citrullinated peptide  
CRP   - C-REACTIVE PROTEIN 
ESR   - ERYTHROCYTE SEDIMENTATION RATE 
HDL   - HIGH DENSITY LIPOPROTEIN 
LDL   -  LOW DENSITY LIPOPROTEIN 
TG   - TRIGLYCERIDE 
TC   - TOTAL CHOLESTEROL 
 
 
  
MASTER CHART FOR CASE GROUP 
S.NO SEX AGE RF ESR CRP OBESITY HDL 
TOTAL 
CHOLESTEROL 
LDL TG 
1 FEMALE 39 NEGATIVE 13 0.7 NO 56 167 115 110 
2 FEMALE 41 NEGATIVE 20 0.8 NO 58 156 113 112 
3 FEMALE 32 NEGATIVE 14 0.4 NO 50 158 112 113 
4 FEMALE 37 NEGATIVE 18 0.5 YES 51 158 100 114 
5 MALE 39 NEGATIVE 19 0.6 NO 59 160 110 116 
6 MALE 48 NEGATIVE 16 0.3 NO 54 167 98 124 
7 MALE 37 NEGATIVE 15 0.6 NO 55 163 97 126 
8 MALE 38 NEGATIVE 18 0.9 NO 52 160 102 127 
9 MALE 40 POSITIVE 33 5.5 NO 32 177 111 121 
  
10 MALE 44 POSITIVE 37 5.1 YES 34 178 99 130 
11 MALE 45 POSITIVE 32 4.9 NO 36 169 102 131 
12 FEMALE 36 POSITIVE 29 2.9 NO 39 178 105 132 
13 FEMALE 32 POSITIVE 43 7.4 NO 43 180 106 123 
14 FEMALE 39 POSITIVE 66 13.4 YES 39 187 104 142 
15 FEMALE 38 POSITIVE 62 14.2 NO 40 198 110 152 
16 FEMALE 39 POSITIVE 48 9.8 NO 41 160 111 142 
17 FEMALE 38 POSITIVE 59 11 NO 39 177 107 143 
18 FEMALE 39 POSITIVE 35 3.9 NO 40 176 105 137 
19 FEMALE 31 POSITIVE 39 4.2 NO 40 168 105 138 
20 FEMALE 40 POSITIVE 44 8.5 NO 41 157 109 132 
21 FEMALE 38 POSITIVE 54 9.9 YES 37 170 111 140 
  
22 FEMALE 30 POSITIVE 28 3.2 NO 46 177 117 141 
23 FEMALE 31 POSITIVE 89 18.5 NO 34 210 134 174 
24 FEMALE 46 POSITIVE 45 8.5 NO 40 189 121 153 
25 FEMALE 33 POSITIVE 69 14.5 NO 36 199 120 162 
26 FEMALE 32 POSITIVE 39 4.9 NO 45 187 98 132 
27 FEMALE 41 POSITIVE 32 4.5 NO 43 178 89 150 
28 FEMALE 38 POSITIVE 57 9.9 NO 39 179 100 156 
29 FEMALE 38 POSITIVE 45 8.8 NO 42 160 90 132 
30 FEMALE 37 POSITIVE 58 11 YES 40 162 97 167 
31 FEMALE 38 POSITIVE 44 9.5 NO 45 173 99 153 
32 FEMALE 46 POSITIVE 79 15.9 NO 33 213 152 178 
33 FEMALE 32 POSITIVE 58 9.6 NO 36 175 100 163 
  
34 FEMALE 34 POSITIVE 28 2.1 NO 48 184 94 145 
35 FEMALE 47 POSITIVE 60 12 NO 38 179 88 135 
36 FEMALE 37 POSITIVE 59 9.9 NO 34 166 105 134 
37 FEMALE 38 POSITIVE 46 8.6 NO 38 188 102 129 
38 FEMALE 33 POSITIVE 31 2.9 NO 43 177 93 123 
39 FEMALE 40 POSITIVE 61 10.4 NO 36 171 99 160 
40 FEMALE 42 POSITIVE 120 22.4 NO 29 256 156 190 
41 FEMALE 39 POSITIVE 65 11.7 NO 33 182 112 153 
42 FEMALE 33 POSITIVE 88 17.2 YES 31 223 154 149 
43 FEMALE 36 POSITIVE 19 1.1 NO 52 184 99 119 
44 FEMALE 32 POSITIVE 90 19.4 NO 30 234 145 164 
45 FEMALE 39 POSITIVE 55 10.6 YES 34 181 102 133 
  
46 FEMALE 34 POSITIVE 42 8.1 NO 38 190 112 143 
47 FEMALE 33 POSITIVE 47 9.8 NO 39 167 109 142 
48 FEMALE 31 POSITIVE 72 12.4 NO 35 221 136 156 
49 FEMALE 33 POSITIVE 45 8.8 NO 38 185 123 158 
50 FEMALE 41 POSITIVE 33 3.9 NO 40 179 110 123 
  
MASTER CHART FOR CONTROL GROUP 
S.NO SEX AGE RF ESR CRP OBESITY HDL 
TOTAL 
CHOLESTEROL 
LDL TG 
1 FEMALE 33 NEGATIVE 13 0.2 NO 56 167 115 110 
2 FEMALE 34 NEGATIVE 20 0.3 NO 58 156 113 112 
3 FEMALE 37 NEGATIVE 14 0.4 NO 50 158 112 113 
4 FEMALE 43 NEGATIVE 18 0.5 YES 51 158 100 114 
5 MALE 32 NEGATIVE 19 0.6 NO 50 160 110 116 
6 MALE 36 NEGATIVE 16 0.3 NO 52 167 98 124 
7 MALE 37 NEGATIVE 15 0.3 NO 49 163 97 126 
8 MALE 38 NEGATIVE 18 0.9 NO 48 160 102 127 
9 MALE 39 NEGATIVE 14 0.8 NO 46 177 111 121 
  
10 MALE 40 NEGATIVE 16 1 YES 49 178 99 130 
11 MALE 41 NEGATIVE 16 0.1 NO 50 169 102 131 
12 FEMALE 42 NEGATIVE 18 0.2 NO 51 178 105 132 
13 FEMALE 43 NEGATIVE 13 0.3 NO 52 180 106 123 
14 FEMALE 43 NEGATIVE 9 0.4 NO 53 187 104 118 
15 FEMALE 46 NEGATIVE 11 0.5 NO 54 178 110 139 
16 FEMALE 45 NEGATIVE 12 0.6 NO 55 160 111 142 
17 FEMALE 38 NEGATIVE 12 0.7 NO 56 177 107 143 
18 FEMALE 39 NEGATIVE 13 0.8 NO 57 176 105 137 
19 FEMALE 31 NEGATIVE 9 0.9 NO 58 168 105 138 
20 FEMALE 40 NEGATIVE 11 1 NO 59 157 109 132 
21 FEMALE 38 NEGATIVE 10 1.1 YES 60 170 111 140 
  
22 FEMALE 30 NEGATIVE 12 1 NO 51 177 117 141 
23 FEMALE 31 NEGATIVE 13 0.9 NO 52 178 121 119 
24 FEMALE 46 NEGATIVE 14 0.8 NO 54 180 123 137 
25 FEMALE 33 NEGATIVE 17 0.7 NO 49 170 120 139 
26 FEMALE 32 NEGATIVE 11 0.4 NO 50 167 98 132 
27 FEMALE 41 NEGATIVE 12 0.4 NO 55 178 89 120 
28 FEMALE 38 NEGATIVE 13 0.8 NO 52 179 100 131 
29 FEMALE 38 NEGATIVE 14 0.9 NO 51 160 90 132 
30 FEMALE 37 NEGATIVE 14 0.9 YES 59 162 97 145 
31 FEMALE 38 NEGATIVE 15 0.8 NO 58 173 99 123 
32 FEMALE 46 NEGATIVE 16 0.9 NO 57 189 109 132 
33 FEMALE 32 NEGATIVE 12 0.8 NO 56 175 100 100 
  
34 FEMALE 34 NEGATIVE 19 1.2 NO 59 184 94 105 
5 FEMALE 47 NEGATIVE 14 0.7 NO 54 179 88 107 
36 FEMALE 37 NEGATIVE 16 0.2 NO 53 166 105 134 
37 FEMALE 38 NEGATIVE 15 0.4 NO 62 188 102 129 
38 FEMALE 33 NEGATIVE 11 0.6 NO 52 177 93 123 
39 FEMALE 40 NEGATIVE 13 0.6 NO 51 171 99 106 
40 FEMALE 42 NEGATIVE 17 0.9 NO 55 180 111 109 
41 FEMALE 39 NEGATIVE 15 0.7 NO 63 182 112 101 
42 FEMALE 33 NEGATIVE 13 0.5 YES 62 169 99 129 
43 FEMALE 36 NEGATIVE 15 0.4 NO 61 184 98 119 
44 FEMALE 31 NEGATIVE 12 0.2 NO 60 188 106 116 
45 FEMALE 32 NEGATIVE 9 0.4 YES 59 181 102 114 
  
46 FEMALE 37 NEGATIVE 10 0.4 NO 58 190 112 113 
47 FEMALE 36 NEGATIVE 10 0.1 NO 56 167 109 112 
48 FEMALE 34 NEGATIVE 11 0.2 NO 54 184 117 120 
49 FEMALE 33 NEGATIVE 14 0.8 NO 50 185 110 132 
50 FEMALE 40 NEGATIVE 13 0.9 NO 49 179 113 123 
 
  
 
  
 
 
 
  
 
